CPG-7909 (PF-3512676, ProMune®):: toll-like receptor-9 agonist in cancer therapy

被引：47
作者：
Murad, Yanal M.
Clay, Timothy M.
Lyerly, H. Kim
Morse, Michael A.
机构：
[1] Duke Univ, Med Ctr, Program Mol Therapeut, Ctr Comprehens Canc,Dept Surg, Durham, NC 27710 USA
[2] Duke Univ, Med Ctr, Program Mol Therapeut, Duke Comprehens Canc Ctr,Dept Pathol & Immunol, Durham, NC 27710 USA
[3] Duke Univ, Med Ctr, Program Mol Therapeut, Comprehens Canc Ctr,Dept Med, Durham, NC 27710 USA
来源：
EXPERT OPINION ON BIOLOGICAL THERAPY | 2007年 / 7卷 / 08期
关键词：
adjuvant; CPG-7909; PF-3512676; ProMune; TLR9;
D O I：
10.1517/14712598.7.8.1257
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
Stimulation of toll-like receptor (TLR)9 activates human plasmacytoid dendritic cells and B cells, and induces potent innate immune responses in preclinical tumor models and in patients. CpG oligodeoxynucleoticles (ODNs) are TLR9 agonists that show promising results as vaccine adjuvants and in the treatment of cancers, infections, asthma and allergy. PF-3512676 (ProMune((R))) was developed as a TLR9 agonist for the treatment of cancer as monotherapy and as an adjuvant in combination with chemo- and immunotherapy. Phase I and II trials have tested this drug in several hematopoietic and solid tumors. Pfizer has initiated Phase III trials to test PF-3512676 in combination with standard chemotherapy for non-small-cell lung cancer.
引用
收藏
页码：1257 / 1266
页数：10
相关论文
共 83 条
[1]   Functional diversity of helper T lymphocytes [J].
Abbas, AK ;
Murphy, KM ;
Sher, A .
NATURE, 1996, 383 (6603) :787-793
[2]  
Ahmad-Nejad P, 2002, EUR J IMMUNOL, V32, P1958, DOI 10.1002/1521-4141(200207)32:7<1958::AID-IMMU1958>3.0.CO
[3]  
2-U
[4]  
Akira S, 2006, CURR TOP MICROBIOL, V311, P1
[5]   Toll-like receptors: critical proteins linking innate and acquired immunity [J].
Akira, S ;
Takeda, K ;
Kaisho, T .
NATURE IMMUNOLOGY, 2001, 2 (08) :675-680
[6]   Toll-like receptor signalling [J].
Akira, S ;
Takeda, K .
NATURE REVIEWS IMMUNOLOGY, 2004, 4 (07) :499-511
[7]   Mouse type IIFN-producing cells are immature APCs with plasmacytoid morphology [J].
Asselin-Paturel, C ;
Boonstra, A ;
Dalod, M ;
Durand, I ;
Yessaad, N ;
Dezutter-Dambuyant, C ;
Vicari, A ;
O'Garra, A ;
Biron, C ;
Brière, F ;
Trinchieri, G .
NATURE IMMUNOLOGY, 2001, 2 (12) :1144-1150
[8]   Combination of a CpG-oligodeoxynucleotide and a topoisomerase I inhibitor in the therapy of human tumour xenografts [J].
Balsari, A ;
Tortoreto, M ;
Besusso, D ;
Petrangolini, G ;
Sfondrini, L ;
Maggi, R ;
Ménard, S ;
Pratesi, G .
EUROPEAN JOURNAL OF CANCER, 2004, 40 (08) :1275-1281
[9]   Intracellular localization of Toll-like receptor 9 prevents recognition of self DNA but facilitates access to viral DNA [J].
Barton, GM ;
Kagan, JC ;
Medzhitov, R .
NATURE IMMUNOLOGY, 2006, 7 (01) :49-56
[10]   Human TLR9 confers responsiveness to bacterial DNA via species-specific CpG motif recognition [J].
Bauer, S ;
Kirschning, CJ ;
Häcker, H ;
Redecke, V ;
Hausmann, S ;
Akira, S ;
Wagner, H ;
Lipford, GB .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (16) :9237-9242
123456789